CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

Call Start: 12:45 January 1, 0000 1:27 PM ET

CRISPR Therapeutics AG (NASDAQ:CRSP)
Annual Needham Virtual Healthcare Conference Call
April 08, 2025, 12:45 PM ET

Company Participants

Sam Kulkarni - Chief Executive Officer

Conference Call Participants

Gil Blum - Needham & Company

Gil Blum

Good afternoon, everyone, and thank you for joining me at the second day of the Needham Healthcare Conference. My name is Gil Blum, and I am senior biotech analyst here at Needham & Company with a focus on immune-oncology. It is my pleasure to have with me today Sam Kulkarni, the CEO of CRISPR Therapeutics.

So, as a reminder, for viewers who are watching through our conference portal, you are able to submit questions via the Ask a Question box below the video feed window.

Question-and-Answer Session

Gil Blum

Sam, I'm actually not going to start immediately with CRISPR this time. There's some interesting things going in market these days. If you want to comment on any exposure to tariffs as it relates to CRISPR, that would be super helpful.

Sam Kulkarni

Yeah. Thank you, Gil, for having us. And it is an interesting time in the market. Pleased to say that we have almost no exposure to any of the effects directly as a company from the tariffs. Obviously, there's the effect on the macro market and investor sentiment, but we have a pretty distributed manufacturing network. I think, we make all our allogeneic CAR-T cells here in the US, in Framingham, Massachusetts, but the effect obviously on the overall macro is a very different story.

Gil Blum

All right. Kind of a related question, pretty significant changes in the agency. Has that influenced your conversations and communications with the FDA?

Sam Kulkarni

Yeah. I think, if I may, I think biotech is at an all-time low right